...
首页> 外文期刊>Current Protein and Peptide Science >The Potential Use of Peptides in Cancer Treatment
【24h】

The Potential Use of Peptides in Cancer Treatment

机译:潜在使用肽治疗肽

获取原文
获取原文并翻译 | 示例
           

摘要

Conventional chemotherapeutic drugs have significant limitations. For example, tumors may develop resistance, cancers may relapse after treatment, and the drugs may induce secondary malignancies in the treatment of metastatic cancer. There is still a great need for drugs that are able to destroy cancer cells selectively, that is, to effectively treat slow-growing and dormant cells without being affected by chemoresistance mechanisms. A growing number of studies indicate that peptides may be beneficial for drug discovery and development. Peptides offer minimal immunogenicity, excellent tissue penetrability, low-cost manufacturability, and ease of modification for enhancing in vivo stability and biological activity, properties which make them ideal candidates for cancer treatment. This review highlights recent advances in and future prospects for the application of peptides as therapeutic agents for cancer therapy. We discuss the application of peptides in cancer therapy, alone and in combination with other peptides or small-molecule chemotherapeutic drugs, for use in targeted cancer therapy. Furthermore, we consider the use of peptides as a carrier for targeted molecular imaging in the diagnosis and follow-up treatment of cancer. This account also reviews the challenges of using peptide drugs and ways to overcome these limitations. The results obtained in studies presented in this paper indicate that peptides are promising candidates for targeted cancer therapy.
机译:常规化学治疗药物具有显着的限制。例如,肿瘤可能发生抗性,癌症可能在治疗后复发,并且药物可能诱导次要恶性肿瘤治疗转移性癌症。仍然有一种能够选择性地破坏癌细胞的药物,即有效治疗缓慢生长和休眠细胞而不受化学渗透机制的影响。越来越多的研究表明,肽可能有利于药物发现和发育。肽提供最小的免疫原性,优异的组织渗透性,低成本的可制造性,以及易于增强体内稳定性和生物活性的易用性,使其成为癌症治疗理想候选人的性质。本综述突出了肽应用肽作为癌症疗法的治疗剂的最新进展和未来前景。我们讨论肽在癌症疗法中的应用,单独和与其他肽或小分子化学治疗药物组合,用于靶向癌症治疗。此外,我们考虑使用肽作为靶向分子成像的载体诊断和随访治疗癌症的载体。此账户还审查使用肽药物和克服这些限制的挑战。本文提出的研究中获得的结果表明,肽是针对靶向癌症治疗的候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号